<DOC>
	<DOCNO>NCT02257736</DOCNO>
	<brief_summary>The purpose study compare radiographic progression-free survival ( rPFS ) apalutamide combination abiraterone acetate ( AA ) plus prednisone prednisolone ( AAP ) AAP participant chemotherapy-naive ( participant receive chemotherapy [ treatment cancer use drug ] ) metastatic castration-resistant prostate cancer ( mCRPC ) ( cancer prostate gland [ gland make fluid aid movement sperm ] ) .</brief_summary>
	<brief_title>An Efficacy Safety Study Apalutamide ( JNJ-56021927 ) Combination With Abiraterone Acetate Prednisone Versus Abiraterone Acetate Prednisone Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer ( mCRPC )</brief_title>
	<detailed_description>This randomize ( study drug assign chance ) , double-blind ( neither Investigator participant know treatment ) placebo-controlled multicenter ( 1 hospital medical school team work medical research study ) study determine participant chemotherapy-naive mCRPC benefit addition apalutamide AAP compare AAP alone . The study consist 3 phase : Screening phase ; Treatment phase , Follow-up phase . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Adenocarcinoma prostate Metastatic disease document technetium99m ( 99mTc ) bone scan metastatic lesion compute tomography ( CT ) magnetic resonance imaging ( MRI ) scan ( visceral lymph node disease ) . If lymph node metastasis evidence metastasis , must great equal ( &gt; = ) 2 centimeter ( cm ) long diameter Castrationresistant prostate cancer demonstrate continuous androgen deprivation therapy ( ADT ) , define 3 rise PSA , least 1 week apart last androgen deprivation therapy ( PSA ) &gt; = 2 nanogram per milliliter ( ng/mL ) Participants receive first generation antiandrogen ( eg , bicalutamide , flutamide , nilutamide ) must least 6week washout prior randomization must show continue disease ( PSA ) progression ( increase PSA ) washout period Prostate cancer progression document prostatespecific antigen ( PSA ) accord Prostate Cancer Clinical Trials Working Group ( PCWG2 ) radiographic progression soft tissue accord modify Response Evaluation Criteria Solid Tumors , version 1.1 ( RECIST ) modify base PCWG2 , radiographic progression bone accord PCWG2 Small cell neuroendocrine carcinoma prostate Known brain metastasis Prior chemotherapy prostate cancer , except administer adjuvant/neoadjuvant set Previously treat ketoconazole prostate cancer great 7 day Therapies must discontinue substitute least 4 week prior randomization include follow : ) Medications know low seizure threshold , b ) Herbal nonherbal product may decrease PSA level ( example [ eg ] , saw palmetto , pomegranate ) c ) Any investigational agent At Screening need parenteral oral opioid analgesic ( eg , codeine , dextropropoxyphene )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Prostatic neoplasm</keyword>
	<keyword>JN56021927</keyword>
	<keyword>ZYTIGA</keyword>
	<keyword>Prednisone</keyword>
	<keyword>Abiraterone acetate</keyword>
	<keyword>Apalutamide</keyword>
</DOC>